DCGI: Regulators & inventors should face no obstacles during developing new drugs

In the last two years, more than 180 subject expert committee meetings have been held


Last Updated on November 21, 2021 by The Health Master


At the Global Innovation Summit held by the Indian Pharmaceutical Alliance (IP Alliance), innovators needed to feel confident, and regulators and innovators should not have any barriers during the process of new drug innovation, stated Drugs Controller General of India (DCGI), Dr V G Somani, during the session on creating a regulatory ecosystem to support innovation at the Global Innovation Summit.

“We had to devise a methodology where we, as a regulator, became a facilitator. Without compromising on the quality of data and models required, we multiplied efforts and reduced redundant efforts. In the last two years, more than 180 subject expert committee meetings have been held, ” added DCGI Dr Somani.

Dilip Shanghvi, managing director, Sun Pharmaceutical Industries, is of the view that the research linked incentive is a very good effort to recognise the efforts of the pharmaceutical industry.

Rajesh Gokhale, secretary, Department of Biotechnology, added, “The biotech industry is shifting extremely rapidly and unless we open up our regulatory processes, we will lag behind in doing cutting-edge innovation in the sector.”.

Glenn Saldanha, managing director, Glenmark Pharmaceuticals, added, during C-19, Indian drug regulators were quick to approve drugs and we are on the right track towards creating a research ecosystem in India.

‘The dialogue between the industry and the regulator on innovation should be ongoing. We have to work together to drive the industry’,” added Sanjay Singh, CEO, Gennova Biopharmaceuticals.

“We are at an inflection point. The future is in innovation, and India has all the elements, like talent, capability, and intent, to move forward with innovation, ” added Satish Reddy, chairman, Dr. Reddy’s Laboratories, in the closing remarks.

The Indian Pharmaceutical Alliance represents research-based pharmaceutical companies in India. It is an alliance of 24 leading Indian pharmaceutical companies, committed to patient care in India and across the world.

Eli Lilly files litigation against 20 Indian Pharma Companies

Experts ask Govt to bring list of OTC Drugs

BDR Pharma launches Antibiotics to treat these infections

IPC to organize webinar on Key role of medical device industry…

Natco Pharma launches FDC Trifluridine & Tipiracil first time in India

Retired FDA officials are promoting Generic Drugs in innovative ways

No retention or renewal fees after one time registration of ASU products

International Conference on National Education Policy will be held at …

IPC adds new impurities and Reference Standards: Download the list

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner